Case Report
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Sep 7, 2014; 20(33): 11894-11903
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11894
Table 1 Literature review and case study summary of demographic, clinical presentation, treatment and outcomes of plasmablastic lymphoma of gastrointestinal tract
No.StudyYearAge/sexTumor locationHIV statusGI S/SxB symptomsChemotherapeutic treatmentResponseOutcome
1Mani et al[6]200840/MEsophagus, stomach+Progressive odynophagiaWL, F, NSLACERemissionAlive at 6 mo
2Cha et al[7]201060/MSmall intestine-Dyspnea, melenaWL +CHOPPRRelapse, alive at 24 mo
3Brahmania et al[18]201159/MAno-rectal-Painless rectal bleedingNRCHOPRemissionAlive at 5 yr
4Mihaljevic et al[17]201260/MStomach-Melena1WL +CHOPURDOD after one cycle of CHOP
5Hashimoto et al[15]201270/FStomach-MelenaNRCHOP, VP 16, ifosfamide, carboplatinURDied during treatment
6Chapman-Fredricks et al[14]201246/FStomach+N/V, diarrhea, melenaNREPOCHNLNL
7Bahari et al[11]201217/FSmall intestineNDDiarrhea, distention1F+NLNLDOD before diagnosis made
8Pruneri et al[10]199853/FStomach-Postprandial fullness, stomach acheF+ProMACE-cytaBOMRemissionAlive at 19 mo
9Rajagopal et al[9]200635/MAno-rectal+Rectal bleeding, tenesmus, constipation1WL +CHOPRemissionAlive at 5 mo
10Wang et al[8]201255/MSmall intestine-Distention, vomiting, anorexia1WL +CHOPURDOD at 1.5 mo
11Hatanaka et al[19]201075/MCecum-NL1F +NLNLNL
12Lim et al[16]200947/FAno-rectal+Anal bleeding, pain, fistula for 1 yrNRCHOPReceived 3 cycles of chemotherapy, status unknownNL
13Marques et al[13]201382/FStomach-Melena, epigastric pain, abdominal fullnessWL +CHOPURDOD after 1 cycle of chemotherapy
14Mansoor et al[12]201277/FCecum, colon-Recal bleeding, diarrhea, vomiting1WL +NLURDOD 3 wk after presentation
Case 1Luria et alCurrent case40/MRectal+Hemorr-hoids like sensationsWL +EPOCHPRRelapsed PBL in pelvic, abdomen, bladder 1 yr after PBL diagnosis - loss of follow after it
Case 2Luria et alCurrent case64/MSigmoid colonNRBloody diarrheaNRCHOP-R, Auto-HSCTCRAlive at 44/35 mo
Case 3Luria et alCurrent case41/MTerminal ileumNRAbdominal pain, diarrhea, 35-pound weight lossWL +Hyper-CVAD + VelcadeURProgressive, bladder mass, hepatic metastases, DOD, 17 mo after PBL diagnosed
Case 4Luria et alCurrent case65/MTerminal ileum and cecum-Acute bowel obstructionNAHyper-CVAD + rituximab, auto-HSCTURCR for PBL, but developed tAML and DOD 2 mo after tAML diagnosed and 25 mo after PBL diagnosed
1Accompany abdominal pain; 44/35: 44 mo after diagnosis and 35 mo post transplant; +: Positive; -: Negative; ND: Not done; GI S/Sx: GI tract symptoms and signs; WL: Weight loss; F: Fever; NS: Night sweats; NR: None reported; NL: None listed; CHOP: Cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone; CHOP-R: Cyclophosphamide, doxorubicin, vincristine, prednisone-rituximab; LACE: Lomustine, cytarabine, cyclophosphamide, etoposide; EPOCH: Etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone; proMACE-cytaBOM: Cyclophosphamide, doxorubicin, etoposide cytozar, bleomycin, vincristine, methotrexate and prednisone; Hyper-CVAD: Fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone; PR: Partial remission; UR: Unresponsive to therapy; NA: Not Applicable; DOD: Died of disease.
Table 2 Literature review and case study summary of immunophenotypic variation and available Epstein-Barr Virus/HHV8 data of plasmablastic lymphoma of gastrointestinal tract
No.StudyCD45CD20CD79aPAX5CD38CD138MUM-1Ki-67EBERMYCHHV8
1Mani et al[6]+-+ (W)-ND+NDND+ND-1
2Cha et al[7]ND-+ (F)NDND-+70%-NDND
3Brahmania et al[18]---ND+++70%+NDND
4Mihaljevic et al[17]ND-NDND--+70%-NDND
5Hashimoto et al[15]----ND++100%-NDND
6Chapman-Fredricks et al[14]----ND++> 90%++-1
7Bahari et al[11]+-+NDND+NDNDNDNDND
8Pruneri et al[10]---ND+NDND50%NDNDND
9Rajagopal et al[9]+--ND+NDND80%NDNDND1
10Wang et al[8]--+ND+ (F)+-80%-NDND
11Hatanaka et al[19]---NDND+ND90%NDNDND
12Lim et al[16]ND-NDNDND+ND95%+ND+1
13Marques et al[13]--NDNDND++90%NDNDND
14Mansoor et al[12]+ (W)-+ (W)NDND+ND90%NDNDND
Case 1Luria et al+ (W)-+ (W)NDND+ND80%+ND-
Case 2Luria et al+ (W)--ND+-ND> 90%+NDND
Case 3Luria et al-/+-++ND++75%+NDND
Case 4Luria et alND-+-ND+ND100%NDNDND
1HIV+ patients (x 4). +: Positive; -: Negative; ND: Not done; (W): Weak; (F): Focal; NA: Not applicable; EBER: Epstein-Barr Virus -encoded RNA.